European approval for AbbVies Skyrizi

European approval for AbbVie’s Skyrizi

07:30 EDT 1 May 2019 | PharmaTimes

The approval is for the treatment of moderate to severe plaque psoriasis.

Original Article: European approval for AbbVie’s Skyrizi

More From BioPortfolio on "European approval for AbbVie’s Skyrizi"